Xencor Inc. ( (XNCR) ) has released its Q3 earnings. Here is a breakdown of the information Xencor Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Xencor, Inc. is a clinical-stage biopharmaceutical company that focuses on developing engineered antibody therapeutics for cancer and autoimmune diseases. In its latest earnings report, Xencor reported a net loss of $6.03 million for the third quarter of 2025, a significant improvement from the $47.44 million loss in the same period last year. The company saw an increase in revenue from collaborations, milestones, and royalties, totaling $21 million for the quarter, up from $17.8 million the previous year. Key financial metrics include a decrease in cash and cash equivalents to $28.3 million from $40.9 million at the end of 2024, and a reduction in total assets to $868.8 million from $951.9 million. Despite the net loss, Xencor’s strategic partnerships with companies like Alexion and Incyte have resulted in significant milestone payments and royalty revenues. Looking ahead, Xencor remains focused on advancing its clinical programs and leveraging its partnerships to drive future growth.